Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Jul 31;12(7):1643-1648.
doi: 10.21037/tlcr-23-200. Epub 2023 Jun 1.

First-line management of advanced non-small-cell lung cancer: can we do better?

Christos Chouaïd  1   2 , Isabelle Monnet  1 , Jean-Bernard Auliac  1
Affiliations
Editorial

First-line management of advanced non-small-cell lung cancer: can we do better?

Christos Chouaïd et al. Transl Lung Cancer Res. .
No abstract available

Keywords: Lung cancer; chemotherapy; immunotherapy; management.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-23-200/coif). CC and JBA report consulting fees, travel support and honoraris from AZ, BI, GSK, Roche, Sanofi Aventis, BMS, MSD, Lilly, Novartis, Pfizer, Takeda, Bayer, Janssen, Viatris, Chugai, and Amgen. The authors have no other conflicts of interest to declare.

Comment on

References

    1. Garassino MC, Gadgeel S, Speranza G, et al. Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study. J Clin Oncol 2023;41:1992-8. 10.1200/JCO.22.01989 - DOI - PMC - PubMed
    1. Gogishvili M, Melkadze T, Makharadze T, et al. Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial. Nat Med 2022;28:2374-80. 10.1038/s41591-022-01977-y - DOI - PMC - PubMed
    1. Nishio M, Barlesi F, West H, et al. Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial. J Thorac Oncol 2021;16:653-64. 10.1016/j.jtho.2020.11.025 - DOI - PubMed
    1. Jotte R, Cappuzzo F, Vynnychenko I, et al. Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial. J Thorac Oncol 2020;15:1351-60. 10.1016/j.jtho.2020.03.028 - DOI - PubMed
    1. Reck M, Wehler T, Orlandi F, et al. Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non-Small-Cell Lung Cancer. J Clin Oncol 2020;38:2530-42. 10.1200/JCO.19.03158 - DOI - PMC - PubMed